Literature DB >> 27876197

Vaccination of special populations: Protecting the vulnerable.

Mark Doherty1, Ruprecht Schmidt-Ott2, Jose Ignacio Santos3, Lawrence R Stanberry4, Annika M Hofstetter5, Susan L Rosenthal6, Anthony L Cunningham7.   

Abstract

One of the strategic objectives of the 2011-2020 Global Vaccine Action Plan is for the benefits of immunisation to be equitably extended to all people. This approach encompasses special groups at increased risk of vaccine-preventable diseases, such as preterm infants and pregnant women, as well as those with chronic and immune-compromising medical conditions or at increased risk of disease due to immunosenescence. Despite demonstrations of effectiveness and safety, vaccine uptake in these special groups is frequently lower than expected, even in developed countries with vaccination strategies in place. For example, uptake of the influenza vaccine in pregnancy rarely exceeds 50% in developed countries and, although data are scarce, it appears that only half of preterm infants are up-to-date with routine paediatric vaccinations. Many people with chronic medical conditions or who are immunocompromised due to disease or aging are also under-vaccinated. In the US, coverage among people aged 65years or older was 67% for the influenza vaccine in the 2014-2015 season and 55-60% for tetanus and pneumococcal vaccines in 2013, while the coverage rate for herpes zoster vaccination among those aged 60years or older was only 24%. In most other countries, rates are far lower. Reasons for under-vaccination of special groups include fear of adverse outcomes or illness caused by the vaccine, the inconvenience (and in some settings, cost) of vaccination and lack of awareness of the need for vaccination or national recommendations. There is also evidence that healthcare providers' attitudes towards vaccination are among the most important influences on the decision to vaccinate. It is clear that physicians' adherence to recommendations needs to be improved, particularly where patients receive care from multiple subspecialists and receive little or no care from primary care providers. Copyright Â
© 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Adolescent; Immunocompromised; Older adults; Pregnancy; Preterm; Special group

Mesh:

Year:  2016        PMID: 27876197     DOI: 10.1016/j.vaccine.2016.11.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

Review 1.  CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential.

Authors:  Andrea J Sant; Anthony T DiPiazza; Jennifer L Nayak; Ajitanuj Rattan; Katherine A Richards
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

2.  Practice and attitudes towards immunization among Lebanese obstetricians and gynecologists.

Authors:  Elie Hobeika; Ihab M Usta; Rami Helou; Salma Jabak; Faysal El Kak; Anwar H Nassar
Journal:  Hum Vaccin Immunother       Date:  2018-04-11       Impact factor: 3.452

Review 3.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

Review 4.  Opportunities for pharmacists in vaccinating higher-risk populations.

Authors:  Carolyn Whiskin; Nora Cutcliffe
Journal:  Can Pharm J (Ott)       Date:  2019-10-16

Review 5.  Pharmacists and vaccination in pregnancy.

Authors:  Christine Hughes
Journal:  Can Pharm J (Ott)       Date:  2019-10-11

6.  Identification of Biologically Active Pyrimido[5,4-b]indoles That Prolong NF-κB Activation without Intrinsic Activity.

Authors:  Michael Chan; Alast Ahmadi; Shiyin Yao; Fumi Sato-Kaneko; Karen Messer; Minya Pu; Brandon Nguyen; Tomoko Hayashi; Maripat Corr; Dennis A Carson; Howard B Cottam; Nikunj M Shukla
Journal:  ACS Comb Sci       Date:  2017-07-13       Impact factor: 3.784

7.  Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.

Authors:  Prabhu S Arunachalam; Alexandra C Walls; Nadia Golden; Caroline Atyeo; Stephanie Fischinger; Chunfeng Li; Pyone Aye; Mary Jane Navarro; Lilin Lai; Venkata Viswanadh Edara; Katharina Röltgen; Kenneth Rogers; Lisa Shirreff; Douglas E Ferrell; Samuel Wrenn; Deleah Pettie; John C Kraft; Marcos C Miranda; Elizabeth Kepl; Claire Sydeman; Natalie Brunette; Michael Murphy; Brooke Fiala; Lauren Carter; Alexander G White; Meera Trisal; Ching-Lin Hsieh; Kasi Russell-Lodrigue; Christopher Monjure; Jason Dufour; Skye Spencer; Lara Doyle-Meyers; Rudolph P Bohm; Nicholas J Maness; Chad Roy; Jessica A Plante; Kenneth S Plante; Alex Zhu; Matthew J Gorman; Sally Shin; Xiaoying Shen; Jane Fontenot; Shakti Gupta; Derek T O'Hagan; Robbert Van Der Most; Rino Rappuoli; Robert L Coffman; David Novack; Jason S McLellan; Shankar Subramaniam; David Montefiori; Scott D Boyd; JoAnne L Flynn; Galit Alter; Francois Villinger; Harry Kleanthous; Jay Rappaport; Mehul S Suthar; Neil P King; David Veesler; Bali Pulendran
Journal:  Nature       Date:  2021-04-19       Impact factor: 49.962

8.  Reasons of the delayed vaccination, recommendations and safety of vaccination in children with congenital heart disease in Zhejiang, China.

Authors:  Mingyan Li; Chai Ji; Yan Zeng; Dan Yao; Xia Wang; Jie Shao
Journal:  Hum Vaccin Immunother       Date:  2021-02-12       Impact factor: 3.452

Review 9.  Vaccination of immune compromised children-an overview for physicians.

Authors:  Laure F Pittet; Klara M Posfay-Barbe
Journal:  Eur J Pediatr       Date:  2021-03-05       Impact factor: 3.183

10.  Vaccination timeliness and completeness among preterm and low birthweight infants: a national cohort study.

Authors:  Dov Bary-Weisberg; Chen Stein-Zamir
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.